Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Early Phase 1

Recruiting

Conditions: T-cell Lymphoma

Interventions: Biological: hNeo-T
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-01-25

Last Posted Date: 2024-03-12

Lead Sponsor: BGI, China

Target Recruit Count: 6

Registration Number: NCT06224049

Locations: 🇨🇳
ShenZhen University General Hospital, Shenzhen, Guangdong, China

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis

Phase 1

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: CC-97540
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-01-23

Last Posted Date: 2024-12-18

Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Target Recruit Count: 98

Registration Number: NCT06220201

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇬🇧
Salford Royal Hospital, Salford, Manchester, United Kingdom
🇬🇧
Manchester Royal Infirmary, Manchester, United Kingdom

and more 34 locations

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Phase 3

Withdrawn

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Biological: Liso-cel
Drug: Idelalisib
Drug: Fludarabine
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Bendamustine

First Posted Date: 2024-01-16

Last Posted Date: 2024-04-02

Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Registration Number: NCT06205290

Locations: 🇺🇸
Local Institution - 0068, Morgantown, West Virginia, United States
🇺🇸
Local Institution - 0121, New York, New York, United States
🇫🇷
Local Institution - 0036, Montpellier, Languedoc-Roussillon, France

and more 45 locations

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

Phase 1

Not yet recruiting

Conditions: Melanoma Stage IV
Melanoma
Melanoma Stage III

Interventions: Biological: ADP-TILIL7
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Drug: Proleukin

First Posted Date: 2024-01-12

Last Posted Date: 2024-01-12

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 10

Registration Number: NCT06204991

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Dual-Energy Computed Tomography
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Magnetic Resonance Imaging
Drug: Melphalan
Procedure: Multigated Acquisition Scan
Biological: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total Marrow and Lymphoid Irradiation

First Posted Date: 2024-01-08

Last Posted Date: 2024-11-06

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 33

Registration Number: NCT06195891

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Efficacy & Safety for LN144 with Pembrolizumab with High Risk Stage IIIb-dResectable Melanoma

Phase 1

Recruiting

Conditions: Stage IIID Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma

Interventions: Biological: LN-144
Drug: Cyclophosphamide
Drug: Mesna
Drug: Fludarabine
Biological: Interleukin-2 (IL-2)
Drug: Pembrolizumab

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-05

Lead Sponsor: James Isaacs, MD

Target Recruit Count: 12

Registration Number: NCT06190249

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Phase 1

Recruiting

Conditions: Recurrent Chronic Lymphocytic Leukemia
Recurrent Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Mantle Cell Lymphoma
Refractory Transformed Chronic Lymphocytic Leukemia
B-Cell Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Biological: Autologous BAFFR-targeting CAR T Cells
Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2024-01-05

Last Posted Date: 2024-07-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 27

Registration Number: NCT06191887

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Biological: MSGV1-PSCA-8T28Z
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-20

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 30

Registration Number: NCT06193486

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting

Conditions: Philadelphia-Positive ALL
Lymphoblastic Leukemia
Adult ALL

Interventions: Drug: Vincristine
Drug: Dexamethasone
Drug: Imatinib
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Ponatinib
Procedure: allogeneic stem cell transplantation
Procedure: Total body irradiation
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-12-19

Last Posted Date: 2023-12-19

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 150

Registration Number: NCT06175702

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Not Applicable

Recruiting

Conditions: Non-hodgkin Lymphoma,B Cell

Interventions: Biological: CART-19 and 20 cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-12-07

Last Posted Date: 2023-12-07

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT06160362

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy